Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

DOI:10.1016/S1470-2045(26)00193-2
作者：Herui Yao,?Qingyuan Zhang,?Huiping Li,?Yongmei Yin,?Shusen Wang,?Quchang Ouyang,?Tao Sun,?Wei Li,?Xiaojia Wang,?Min Yan,?Biyun Wang,?Jing Cheng,?Zhongsheng Tong,?Wei Wei,?Xinshuai Wang,?Weimin Xie,?Zh
文献类型：期刊论文
补充材料：仅需补充材料